Human CD1D gene expression is regulated by LEF-1 through distal promoter regulatory elements

Journal of Immunology

Volumn 184, Issue 9, 2010, Pages 5047-5054

  Chen, Qiao Yi ^a   Zhang, Tao ^b   Pincus, Seth H ^b,c   Wu, Shixiu ^d   Ricks, David ^b   Liu, Donald ^f   Sun, Zhongsheng ^e   Maclaren, Noel ^g   Lan, Michael S ^b,c  

^a Qugene Corporation   (United States)

^b CHILDREN S HOSPITAL   (United States)

^c LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d WENZHOU MEDICAL UNIVERSITY   (China)

^e INSTITUTE OF PSYCHOLOGY   (China)

^f UNIVERSITY OF CHICAGO   (United States)

^g BioSeek Endocrine Clinics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD1D ANTIGEN; HISTONE DEACETYLASE 1; HISTONE H3; HISTONE H4; LYMPHOID ENHANCER FACTOR 1; SMALL INTERFERING RNA; WNT PROTEIN; CD1D PROTEIN, HUMAN; LEF1 PROTEIN, HUMAN; REPRESSOR PROTEIN;

ACETYLATION; ARTICLE; BIOLOGICAL ACTIVITY; CELL TYPE; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENE SEQUENCE; GENE SILENCING; IMMUNOSURVEILLANCE; LEUKEMIA CELL LINE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN PROTEIN INTERACTION; REGULATORY SEQUENCE; SIGNAL TRANSDUCTION; BIOSYNTHESIS; CELL STRAIN K 562; DRUG ANTAGONISM; GENETICS; HUMAN; IMMUNOLOGY; METABOLISM; NATURAL KILLER T CELL; PHYSIOLOGY;

ANTIGENS, CD1D; DOWN-REGULATION; GENE KNOCKDOWN TECHNIQUES; HUMANS; JURKAT CELLS; K562 CELLS; LYMPHOID ENHANCER-BINDING FACTOR 1; NATURAL KILLER T-CELLS; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; REPRESSOR PROTEINS; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; WNT PROTEINS;

EID: 77954473128     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0901912     Document Type: Article

References (40)

1. Dougan, S. K., A. Kaser, and R. S. Blumberg. 2007. CD1 expression on antigen-presenting cells. Curr. Top. Microbiol. Immunol. 314: 113-141.
2. Porcelli, S. A., and R. L. Modlin. 1999. The CD1 system: antigen-presenting molecules for T cell recognition of lipids and glycolipids. Annu. Rev. Immunol. 17: 297-329.
3. Canchis, P. W., A. K. Bhan, S. B. Landau, L. Yang, S. P. Balk, and R. S. Blumberg. 1993. Tissue distribution of the non-polymorphic major histocompatibility complex class I-like molecule, CD1d. Immunology 80: 561-565.
4. Exley, M., J. Garcia, S. B. Wilson, F. Spada, D. Gerdes, S. M. Tahir, K. T. Patton, R. S. Blumberg, S. Porcelli, A. Chott, and S. P. Balk. 2000. CD1d structure and regulation on human thymocytes, peripheral blood T cells, B cells and monocytes. Immunology 100: 37-47.
5. Blumberg, R. S., C. Terhorst, P. Bleicher, F. V. McDermott, C. H. Allan, S. B. Landau, J. S. Trier, and S. P. Balk. 1991. Expression of a nonpolymorphic MHC class I-like molecule, CD1D, by human intestinal epithelial cells. J. Immunol. 147: 2518-2524.
6. McMichael, A. J., J. R. Pilch, G. Galfré, D. Y. Mason, J. W. Fabre, and C. Milstein. 1979. A human thymocyte antigen defined by a hybrid myeloma monoclonal antibody. Eur. J. Immunol. 9: 205-210.
7. Amiot, M., A. Bernard, B. Raynal, W. Knapp, C. Deschildre, and L. Boumsell. 1986. Heterogeneity of the first cluster of differentiation: characterization and epitopic mapping of three CD1 molecules on normal human thymus cells. J. Immunol. 136: 1752-1758.
8. Kahn-Perles, B., J. Wietzerbin, D. H. Caillol, and F. Lemonnier. 1985. Delineation of three subsets of class I human T antigens (HTA) on Molt-4 cells: serologic and regulatory relationship to HLA class I antigens. J. Immunol. 134: 1759-1765.
9. Kawano, T., J. Cui, Y. Koezuka, I. Toura, Y. Kaneko, K. Motoki, H. Ueno, R. Nakagawa, H. Sato, E. Kondo, et al. 1997. CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides. Science 278: 1626-1629.
10. Joyce, S. 2001. CD1d and natural T cells: how their properties jump-start the immune system. Cell. Mol. Life Sci. 58: 442-469.
11. + NKT cells against normal and malignant hematological cells in vitro: a comparative study with NK cells or OKT3 activated T lymphocytes or with adult peripheral blood NKT cells. Cancer Immunol. Immunother. 51: 1-8.
12. Metelitsa, L. S., O. V. Naidenko, A. Kant, H. W. Wu, M. J. Loza, B. Perussia, M. Kronenberg, and R. C. Seeger. 2001. Human NKT cells mediate antitumor cytotoxicity directly by recognizing target cell CD1d with bound ligand or indirectly by producing IL-2 to activate NK cells. J. Immunol. 167: 3114-3122.
13. Miyamoto, K., S. Miyake, and T. Yamamura. 2001. A synthetic glycolipid prevents autoimmune encephalomyelitis by inducing TH2 bias of natural killer T cells. Nature 413: 531-534.
14. Sharif, S., G. A. Arreaza, P. Zucker, Q. S. Mi, J. Sondhi, O. V. Naidenko, M. Kronenberg,Y.Koezuka, T. L.Delovitch, J. M. Gombert, et al. 2001. Activation of natural killer T cells by alpha-galactosylceramide treatment prevents the onset and recurrence of autoimmune type 1 diabetes. Nat. Med. 7: 1057-1062.
15. Hong, S., M. T. Wilson, I. Serizawa, L. Wu, N. Singh, O. V. Naidenko, T. Miura, T. Haba, D. C. Scherer, J. Wei, et al. 2001. The natural killer T-cell ligand alpha-galactosylceramide prevents autoimmune diabetes in non-obese diabetic mice. Nat. Med. 7: 1052-1056.
16. Naumov, Y. N., K. S. Bahjat, R. Gausling, R. Abraham, M. A. Exley, Y. Koezuka, S. B. Balk, J. L. Strominger, M. Clare-Salzer, and S. B.Wilson. 2001.Activation of CD1d-restricted T cells protects NOD mice from developing diabetes by regulating dendritic cell subsets. Proc. Natl. Acad. Sci. USA 98: 13838-13843.
17. Chen, Q. Y., and N. Jackson. 2004. Human CD1D gene has TATA boxless dual promoters: an SP1-binding element determines the function of the proximal promoter. J. Immunol. 172: 5512-5521.
18. van de Wetering, M., M. Oosterwegel, D. Dooijes, and H. Clevers. 1991. Identification and cloning of TCF-1, a T lymphocyte-specific transcription factor containing a sequence-specific HMG box. EMBO J. 10: 123-132.
19. Travis, A., A. Amsterdam, C. Belanger, and R. Grosschedl. 1991. LEF-1, a gene encoding a lymphoid-specific protein with an HMG domain, regulates T-cell receptor alpha enhancer function. Genes Dev. 5: 880-894.
20. Waterman, M. L., W. H. Fischer, and K. A. Jones. 1991. A thymus-specific member of the HMG protein family regulates the human T cell receptor C alpha enhancer. Genes Dev. 5: 656-669.
21. Reya, T., and H. Clevers. 2005. Wnt signalling in stem cells and cancer. Nature 434: 843-850.
22. Rubinfeld, B., I. Albert, E. Porfiri, C. Fiol, S. Munemitsu, and P. Polakis. 1996. Binding of GSK3beta to the APC-beta-catenin complex and regulation of complex assembly. Science 272: 1023-1026.
23. Nelson, W. J., and R. Nusse. 2004. Convergence of Wnt, beta-catenin, and cadherin pathways. Science 303: 1483-1487.
24. He, X. 2003. A Wnt-Wnt situation. Dev. Cell 4: 791-797.
25. Spanoudakis, E., M. Hu, K. Naresh, E. Terpos, V. Melo, A. Reid, I. Kotsianidis, S. Abdalla, A. Rahemtulla, and A. Karadimitris. 2009. Regulation of multiple myeloma survival and progression by CD1d. Blood 113: 2498-2507.
26. Calabi, F., J. M. Jarvis, L. Martin, and C. Milstein. 1989. Two classes of CD1 genes. Eur. J. Immunol. 19: 285-292.
27. den Dunnen, J. T., and S. E. Antonarakis. 2001. Nomenclature for the description of human sequence variations. Hum. Genet. 109: 121-124.
28. Riese, J., X. Yu, A. Munnerlyn, S. Eresh, S. C. Hsu, R. Grosschedl, and M. Bienz. 1997. LEF-1, a nuclear factor coordinating signaling inputs from wingless and decapentaplegic. Cell 88: 777-787.
29. Billin, A. N., H. Thirlwell, and D. E. Ayer. 2000. Beta-catenin-histone deacetylase interactions regulate the transition of LEF1 from a transcriptional repressor to an activator. Mol. Cell. Biol. 20: 6882-6890.
30. Hebenstreit, D., M. Giaisi, M. K. Treiber, X. B. Zhang, H. F. Mi, J. Horejs-Hoeck, K. G. Andersen, P. H. Krammer, A. Duschl, and M. Li-Weber. 2008. LEF-1 negatively controls interleukin-4 expression through a proximal promoter regulatory element. J. Biol. Chem. 283: 22490-22497.
31. Gustavson, M. D., H. C. Crawford, B. Fingleton, and L. M. Matrisian. 2004. Tcf binding sequence and position determines beta-catenin and Lef-1 responsiveness of MMP-7 promoters. Mol. Carcinog. 41: 125-139.
32. Geng, Y., P. Laslo, K. Barton, and C. R. Wang. 2005. Transcriptional regulation of CD1D1 by Ets family transcription factors. J. Immunol. 175: 1022-1029.
33. Chen, Q., and A. C. Ross. 2007. Retinoic acid regulates CD1d gene expression at the transcriptional level in human and rodent monocytic cells. Exp. Biol. Med. (Maywood) 232: 488-494.
34. He, T. C., A. B. Sparks, C. Rago, H. Hermeking, L. Zawel, L. T. da Costa, P. J. Morin, B. Vogelstein, and K. W. Kinzler. 1998. Identification of c-MYC as a target of the APC pathway. Science 281: 1509-1512.
35. Tetsu, O., and F. McCormick. 1999. Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 398: 422-426.
36. Shtutman, M., J. Zhurinsky, I. Simcha, C. Albanese, M. D'Amico, R. Pestell, and A. Ben-Ze'ev. 1999. The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway. Proc. Natl. Acad. Sci. USA 96: 5522-5527.
37. Román-Gómez, J., L. Cordeu, X. Agirre, A. Jiménez-Velasco, E. San José-Eneriz, L. Garate, M. J. Calasanz, A. Heiniger, A. Torres, and F. Prosper. 2007. Epigenetic regulation of Wnt-signaling pathway in acute lymphoblastic leukemia. Blood 109: 3462-3469.
38. Ysebaert, L., G. Chicanne, C. Demur, F. De Toni, N. Prade-Houdellier, J. B. Ruidavets, V. Mansat-De Mas, F. Rigal-Huguet, G. Laurent, B. Payrastre, et al. 2006. Expression of beta-catenin by acute myeloid leukemia cells predicts enhanced clonogenic capacities and poor prognosis. Leukemia 20: 1211-1216.
39. Chen, C. C., J. P. Gau, J. Y. You, K. D. Lee, Y. B. Yu, C. H. Lu, J. T. Lin, C. Lan, W. H. Lo, J. M. Liu, and C. F. Yang. 2009. Prognostic significance of betacatenin and topoisomerase IIalpha in de novo acute myeloid leukemia. Am. J. Hematol. 84: 87-92.
40. Fais, F., C. Tenca, G. Cimino, V. Coletti, S. Zanardi, D. Bagnara, D. Saverino, D. Zarcone, G. De Rossi, E. Ciccone, and C. E. Grossi. 2005. CD1d expression on B-precursor acute lymphoblastic leukemia subsets with poor prognosis. Leukemia 19: 551-556.